当前位置:首页 > 报告详情

第一三共 202501_JPM Conference_slide_Final.pdf

上传人: c** 编号:604005 2025-02-03 24页 1.77MB

1、Striving to Become a Leader in ADCsDAIICHI SANKYO CO.,LTD.Sunao ManabeExecutive Chairperson and CEOJanuary 13,20252Management strategies and plans,financial forecasts,future projections and policies,and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sank

2、yos future prospects.These forward-looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions,premises and future forecasts,and thus,there are various inherent risks as well as uncertainties involved.As such,please note that actual results

3、 of Daiichi Sankyo may diverge materially from Daiichi Sankyos outlook or the content of this material.Furthermore,there is no assurance that any forward-looking statements in this material will be realized.Regardless of the actual results or facts,Daiichi Sankyo is not obliged and does not have in

4、its policy the duty to update the content of this material from the date of this material onward.Some of the compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agencyworldwide as a treatment for indications under investigation.Efficacy and s

5、afety have not been established in areas under investigation.There are no guarantee that these compounds will become commercially available in indications under investigation.Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material,but shall not be obliged to guara

6、ntee the absolute accuracy,appropriateness,completeness and feasibility,etc.of the information described in this material.Furthermore,any information regarding companies,organizations or any other matters outside the Daiichi Sankyo Group that is described within this material has been compiled or ci

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
Daiichi Sankyo是一家致力于创新药物研发的制药公司,其核心业务为抗体药物偶联物(ADCs)。文章概述了公司的战略计划,包括财务预测、研发信息、产品管线及股东回报政策。 关键数据包括: 1. 2024财年,预计公司收入将同比增长228.3亿日元,核心营业利润增长64.7%。 2. 公司已在日本、美国和欧盟提交了针对HER2低表达乳腺癌的ENHERTU®新药申请,预计2024财年产品销售将超过500亿日元。 3. 公司拥有7个基于DXd平台的ADC候选药物,其中DS-9606是第二个平台的首个资产,已在ESMO 2024上展示。 4. 针对肺癌,DATROWAY®已在日本获得批准,并在美国提交了加速批准申请。 5. 公司计划在未来几年内,通过与合作伙伴的合作,扩大5个主要DXd ADC产品的需求,并增强供应链能力。 此外,公司还制定了股东回报政策,目标是在2025财年实现超过16%的ROE和8%的股本效率,并通过连续三年的股息增长和股票回购,提高股东价值。 综上所述,Daiichi Sankyo正通过其创新的ADC产品管线,以及在研产品和已批准产品上的持续投资,朝着成为全球领先的抗癌药物创新者的目标迈进。同时,公司也在不断提升股东回报,致力于实现可持续的业务增长和社会贡献。
"Daiichi Sankyo的未来规划是什么?" "该公司的股东回报政策有哪些亮点?" "Daiichi Sankyo在肿瘤治疗领域的竞争优势是什么?"
客服
商务合作
小程序
服务号
折叠